Latest Renergen (ASX:RLT) News

Renergen Limited and Asp Isotopes Inc. have outlined the process for cash payments to shareholders for fractional entitlements following their share acquisition scheme.

Renergen Limited’s shares will be suspended from ASX trading on December 31, 2025, marking a key step in its acquisition by ASP Isotopes Inc. This suspension follows the formal implementation of a scheme of arrangement agreed earlier this month.

ASPI Isotopes Inc. and Renergen Limited have received regulatory clearance to proceed with their Scheme of Arrangement, setting a detailed timetable for share suspensions, listings, and settlements complicated by cross-border processes.

Renergen Limited and ASP Isotopes Inc. have cleared all conditions for their merger scheme, setting the stage for integration and a production update from the Virginia Gas Project early next year.

Renergen Limited and ASP Isotopes Inc. have secured crucial regulatory approvals and agreed to extend the deadline for completing their Scheme of Arrangement to January 2026, signaling steady progress in their strategic partnership.

BDO South Africa has completed its review of Renergen Limited’s interim financial statements, confirming compliance but highlighting significant uncertainties over the company’s future viability.

Renergen Limited forecasts a significant rise in loss per share for H1 2025, driven by one-off transaction costs and full commissioning expenses. The company’s updated trading statement reveals losses could nearly double compared to last year.

Renergen Limited reports significant progress on its merger with ASP Isotopes, resolves a key dispute with Springbok Solar, and reveals promising exploration developments, while managing production and financial challenges.

Renergen Limited and Springbok Solar Power Plant have resolved a protracted legal dispute over land use rights, enabling both the Virginia Gas and Springbok Solar projects to operate collaboratively in South Africa's Free State.

Renergen Limited forecasts a significant increase in its loss per share for the six months ending August 2025, driven by one-off transaction expenses and full commissioning costs of its Phase 1 plant.

Renergen Limited and ASP Isotopes Inc. have proactively extended the deadline to fulfill outstanding conditions for their Scheme of Arrangement offer to 28 November 2025, following key regulatory approvals and ongoing collaboration.

Renergen Limited has received a crucial Competition Commission approval, enabling it to move forward with integration plans alongside ASP Isotopes Inc despite a slight delay in the Scheme timetable.